Free Trial
NASDAQ:INVO

INVO Bioscience (INVO) Stock Price, News & Analysis

INVO Bioscience logo
$0.75 -0.01 (-1.32%)
(As of 12/20/2024 ET)

About INVO Bioscience Stock (NASDAQ:INVO)

Key Stats

Today's Range
$0.74
$0.78
50-Day Range
$0.73
$1.24
52-Week Range
$0.63
$3.50
Volume
39,601 shs
Average Volume
1.59 million shs
Market Capitalization
$2.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.

Receive INVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for INVO Bioscience and its competitors with MarketBeat's FREE daily newsletter.

INVO Stock News Headlines

INVO Bioscience (NASDAQ:INVO) Trading Down 3.9% - Here's Why
NAYA Biosciences to present insights into mode of action of NY-303
The #1 Coin for November 2024
Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…
NAYA Biosciences Inc (INVO)
See More Headlines

INVO Stock Analysis - Frequently Asked Questions

INVO Bioscience's stock was trading at $1.35 at the start of the year. Since then, INVO shares have decreased by 44.4% and is now trading at $0.75.
View the best growth stocks for 2024 here
.

INVO Bioscience, Inc. (NASDAQ:INVO) posted its earnings results on Monday, November, 15th. The company reported ($4.80) EPS for the quarter, missing the consensus estimate of ($4.00) by $0.80. The firm earned $0.22 million during the quarter, compared to analysts' expectations of $0.25 million.

Shares of INVO Bioscience reverse split before market open on Thursday, July 27th 2023. The 1-20 reverse split was announced on Thursday, July 27th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

INVO Bioscience's top institutional investors include CWC Advisors LLC. (2.64%). Insiders that own company stock include Andrea Goren, Steve Shum, Michael Jos Campbell and Matthew K Szot.
View institutional ownership trends
.

Shares of INVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that INVO Bioscience investors own include NVIDIA (NVDA), NIO (NIO), Tesla (TSLA), Meta Platforms (META), Nikola (NKLA), Broadcom (AVGO) and Bilibili (BILI).

Company Calendar

Last Earnings
11/15/2021
Today
12/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:INVO
Fax
N/A
Employees
25
Year Founded
N/A

Profitability

Net Income
$-8,030,000.00
Net Margins
-122.79%
Pretax Margin
-122.32%

Debt

Sales & Book Value

Annual Sales
$5.77 million
Book Value
($2.06) per share

Miscellaneous

Free Float
3,769,000
Market Cap
$2.86 million
Optionable
No Data
Beta
1.43
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (NASDAQ:INVO) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners